Stockscreener 앱 받기
2.94
2.44%
0.07
전일 마감가:
$2.87
열려 있는:
$2.81
하루 거래량:
35,624
Relative Volume:
0.05
시가총액:
$5.40M
수익:
$6.59M
순이익/손실:
$-18.12M
주가수익비율:
-0.3108
EPS:
-9.4605
순현금흐름:
$-11.45M
1주 성능:
-14.29%
1개월 성능:
-18.33%
6개월 성능:
-25.38%
1년 성능:
-89.42%
1일 변동 폭
$2.80
$2.97
1주일 범위
$2.7001
$3.81
52주 변동 폭
$1.50
$36.65
Hcw Biologics Inc Stock (HCWB) Company Profile
명칭
Hcw Biologics Inc
전화
954-842-2024
주소
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
2.94 | 3.89M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc 주식(HCWB)의 최신 뉴스
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - Vinanet
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics (HCWB) posts higher 2026 revenue but flags going-concern risk - Stock Titan
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCWB Q1 2026 Earnings: Surprise EPS of $2.22 vs. Expected Loss, Yet Shares Slip 3.06%Consensus Miss Rate - Vinanet
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCWB Q1 2026 Earnings: EPS of $2.22 Surges Past Loss EstimatesEarnings Power Value - vinanet.vn
HCW Biologics (HCWB) completes $1.6M exempt equity and warrant sale - Stock Titan
HCW Biologics | D: Filing D - Moomoo
HCWB Q2'26 Earnings: EPS estimate is (1.98) USD - TradingView
Price to earnings forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
HCW Biologics (HCWB) director buys stock, entitled to new warrants - Stock Titan
HCW Biologics Announces $1.6 Million Private Placement Financing - The Globe and Mail
HCWB Q1 2026 Earnings: Surprising Profitability Driven by Non-Operating GainsHigh Growth Earnings - vinanet.vn
HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585 - TradingView
HCW Biologics Prices $1.6 Million Private Placement Offering - marketscreener.com
HCWB Looks 94.1% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
HCW Biologics prices $1.6M private placement offering By Investing.com - Investing.com Canada
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering - GlobeNewswire
HCW Biologics Plans to Put $1.6M Toward Three Drug Programs - Stock Titan
HCWB|HCW Biologics Inc|Price:2.640|Chg%:+0.140 - TradingKey
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HCW Biologics Inc (HCWB) Cash Flow - TradingKey
HCW Biologics (HCWB) Surges 6% as Shares Test Key Resistance Near $2.78Large Cap Trends - vinanet.vn
HCW Biologics Inc (HCWB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HCW Biologics Inc (HCWB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HCW Biologics Q1 2026 Earnings: Massive EPS Beat but Stock Plunges – Market Skepticism Over SustainabilityEPS Estimate Trend - vinanet.vn
TradingKey - TradingKey
HCWB|HCW Biologics Inc|Price:2.500|Chg%:-0.380 - TradingKey
HCWB Q1 2026 Earnings: Surprise Net Income Amid Pre-Revenue StatusGuidance Downgrade Alert - Vinanet
HCW Biologics Inc (HCWB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics Inc. Revenue Breakdown – NASDAQ:HCWB - TradingView
HCW Biologics Inc. (HCWB) Stock Price, News, Quote & History - Yahoo! Finance Canada
HCW Biologics seeks pre-IND meeting with FDA for HCW-11-018b - BioWorld News
HCW Biologics Inc. (HCWB) stock price, news, quote and history - Yahoo Finance UK
HCW Biologics’ Cancer Candidate Targets Tissue Factor in Solid Tumors - Stock Titan
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCWB Q1 2026 Earnings: Significant EPS Surprise Driven by Non-Operating ItemsProfit Inflection Point - vinanet.vn
HCWB Q1 2026 Earnings: Strong EPS Beat Despite Zero Revenue; Stock DeclinesPerformance Review - vinanet.vn
HCW Biologics Q1 2026 Earnings: Positive EPS Surprise Overwhelmed by Revenue AbsenceEarnings Beat Alert - dars.gov.et
HCW Biologics (HCWB) seeks $5.6M in stock sale to fund trials, repay debt - Stock Titan
HCWB Q1 2026 Earnings: A Surprise EPS Beat Masks Operational ChallengesNon-GAAP Earnings - Vinanet
Hcw Biologics Inc (HCWB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hcw Biologics Inc 주식 (HCWB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
0.86%
0.31%
자본화:
|
볼륨(24시간):